SAN DIEGO--(BUSINESS WIRE)--OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, received a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Health (NIH). The grant will fund collaborative research between OncoSec and Old Dominion University (ODU) to evaluate and develop novel electroporation technologies.
Help employers find you! Check out all the jobs and post your resume.
